Trial Profile
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CSOAIMTOAN
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer
- 20 Oct 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 20 Oct 2019 Status changed from not yet recruiting to recruiting.